Savanna Biotherapeutics, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$13M
Investors
30
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Savanna Biotherapeutics, Inc. is a Delaware corporation that filed a Form D with the SEC on June 30, 2025 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Savanna Biotherapeutics, Inc. reported $12,999,997 sold from 30 investors of a $59,999,993 total offering as of the Form D filed June 30, 2025. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is C/O University Lab Partners, Curie Hall, 1 University Drive, Aliso Viejo, CA 92656.
Critical Disclosures
What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.
Reporting lapsed · Form D · last filing June 30, 2025
Offering declared to continue beyond a year; annual amendment 13+ months overdue An issuer that stops filing is the case the going-concern flag cannot catch: the report that would have carried it was never filed.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Jun 30, 2025
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
2
dark
Latest event New filer · Jun 30, 2025
SEC.govInvestor
- 1 filing event with values and deltas, latest 2025-06-30, and alerts on the next one
- 2 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2025-06-30: 2 related persons added and 1 removed against the filing of 2022-11-18; 4 now listed. The names are in the Terminal feed.
Robert Spitale
Executive Officer, Director · Aliso Viejo, CA
Jeffrey W. Bird
Director · Palo Alto, CA
Keith W. Loebner
Director · Palo Alto, CA
Kim W. Kamdar
Director · Nissequogue, NY
Questions About Savanna Biotherapeutics, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Savanna Biotherapeutics, Inc.?
Savanna Biotherapeutics, Inc. is a Delaware corporation that filed a Form D with the SEC on June 30, 2025 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.
Is Savanna Biotherapeutics, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Savanna Biotherapeutics, Inc. filed a Form D with the SEC on June 30, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $12,999,997 sold to 30 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Savanna Biotherapeutics, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Savanna Biotherapeutics, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Savanna Biotherapeutics, Inc. raised?
Savanna Biotherapeutics, Inc. reported $12,999,997 sold from 30 investors of a $59,999,993 total offering as of the Form D filed June 30, 2025.
Who can invest in Savanna Biotherapeutics, Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Savanna Biotherapeutics, Inc.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Savanna Biotherapeutics, Inc. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind Savanna Biotherapeutics, Inc.?
The Form D lists 4 related persons: Robert Spitale, executive officer, director; Jeffrey W. Bird, director; Keith W. Loebner, director; Kim W. Kamdar, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Savanna Biotherapeutics, Inc. located?
The issuer's address on its SEC filings is C/O University Lab Partners, Curie Hall, 1 University Drive, Aliso Viejo, CA 92656. Its phone number of record is 716-969-2573. It is organized under the laws of Delaware.
How long is the Savanna Biotherapeutics, Inc. offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is Savanna Biotherapeutics, Inc.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
